What Selank dosage was used in human studies?

The clearest short human treatment studies reported 2.7 mg per day for 14 days. Papers that specify the route used an intranasal preparation. This was one fixed research protocol, not a tested range and not a personal recommendation. A separate 2020 brain-scan experiment used one 0.2 mg intranasal dose in healthy volunteers.

Did researchers test a Selank dose range?

No. The main treatment reports did not place people into several Selank dose groups to compare results and side effects. Most used the same 2.7 mg daily amount. The 0.2 mg dose from a later brain-scan study answered a different question, so combining those figures into a 0.2-to-2.7 mg treatment range is misleading.

Can a nasal Selank study dose be converted to an injection dose?

No. Nasal and under-the-skin delivery can produce different absorption, and the published studies do not provide a reliable conversion. Promise's product is also a Semax/Selank blend rather than Selank alone. Its dose must match the compounded concentration, route, both ingredients, and the individual prescription written by the reviewing provider.

Why is Semax/Selank blend dosing different?

It is a two-peptide injectable preparation, while the clearest Russian Selank studies examined Selank in nasal form. Semax and Selank have different research histories and are included for different clinical reasons. A provider therefore considers both ingredients, current medications, health history, the dispensed concentration, and the plan for follow-up rather than copying a Selank-only nasal protocol.

Is Selank FDA-approved?

No. Selank is not FDA-approved, and the compounded Semax/Selank formulation offered here is not FDA-approved. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before marketing. A licensed provider may still prescribe a compounded formulation; that choice is made between the patient and the doctor.

Who decides the Semax/Selank dose?

The reviewing provider sets it if the blend is prescribed. The decision includes the reason for the request, mental-health and neurological history, current medications, prior reactions, the injectable route, both peptides, and the pharmacy's dispensed concentration. The individual prescription and label, not a Russian nasal-study number or an online chart, define the applicable amount.

Selank Dosage: What Human Studies Actually Used

Selank dosage doesn't have a single U.S. standard: the clearest Russian human studies report 2.7 mg per day, and the papers that name the route used intranasal delivery, meaning through the nose. They tested short, fixed study protocols, not a range designed to find the best dose. A separate brain-scan experiment used one 0.2 mg nasal dose. None of those numbers converts cleanly to Promise's injectable Semax/Selank blend, so the prescription comes from the reviewing provider, not an online chart.

For the broader question of why Selank was studied, what Selank is used for keeps the evidence and its limits in one place. Here, the narrower question is how researchers chose the amounts.

What Selank dosage did human studies use?

A quick unit translation helps: 1 milligram (mg) equals 1,000 micrograms (mcg). That means 2.7 mg and 2,700 mcg describe the same amount.

Study	What researchers did	What it cannot tell us
2014 comparative study	Sixty adults were assigned to two groups. Thirty received Selank at 2.7 mg per day for 14 days; 30 received phenazepam, a benzodiazepine anti-anxiety drug.	There was no lower- or higher-dose Selank group, and everyone knew which treatment they received.
2012 European Psychiatry report	Twenty adults with generalized anxiety disorder received 2.7 mg per day intranasally.	This was a short conference report with no comparison group described.
2020 brain-scan study	Of 52 healthy volunteers, 16 received one 0.2 mg intranasal dose; the others received Semax or placebo, an inactive comparison. Brain activity was measured after 5 and 20 minutes.	This was not a treatment study and did not test a repeating schedule.

The original Russian report for the 2020 study is important because it gives the route and amount that the shorter English abstract leaves unclear. It also shows why 0.2 to 2.7 mg should not be advertised as a treatment range. Those numbers came from different experiments asking different questions.

Why 2.7 mg is not a personal target

A fixed trial amount answers one modest question: what happened under that particular protocol? It does not show whether less would have produced the same result, whether more would have added risk, or where an individual dose should begin. Those questions require a dose-finding study with several groups. The published human work did not do that.

The evidence is also smaller than a dosage chart makes it look. A 2008 study indexed by PubMed compared 30 people receiving Selank with 32 receiving medazepam. Its PubMed record catalogs intranasal administration, but the accessible abstract does not report an amount. Filling that blank with a number borrowed from another paper does not make the number part of this study.

The honest summary is narrow: several short Russian reports used 2.7 mg per day, while one later imaging experiment used 0.2 mg once. None established an optimal dose.

The route changes the answer

The Russian numbers came from nasal preparations. Promise's Semax/Selank product is a compounded injectable vial, a prescription preparation made by a pharmacy for an individual patient. It is given under the skin and contains both peptides, short chains of amino acids, in one preparation. That is a different route and a different product.

Route changes absorption, or how a drug moves into the body. A milligram placed in the nose does not automatically create the same exposure, meaning the amount that reaches the body, as a milligram injected under the skin. Adding Semax also changes the clinical question because the Russian Selank-only protocols did not test the two-peptide blend.

There is therefore no honest nasal-to-injection conversion hiding in the papers. The prescribed amount has to match the actual formulation and the provider's plan.

Why online dosage guides overstate the evidence

Most confident-looking guides make one of three moves: they turn the 2.7 mg research protocol into a universal target, present the single 0.2 mg scan dose as the low end of a dose ladder, or convert a nasal liquid into drops or sprays without knowing the concentration and device. Each move adds precision the studies did not earn.

The source papers have real limits: small groups, short follow-up, little independent replication outside Russia, and no modern trial comparing several Selank amounts. They also do not establish a dose for ongoing everyday stress or for an injected Semax/Selank blend. More decimal places cannot fix those gaps.

Selank is not FDA-approved, and the compounded Semax/Selank formulation offered here is not FDA-approved. The FDA explains that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

As of September 6, 2026, the day this article was written, the FDA's July 23–24 advisory-committee materials covered Semax, the other peptide in Promise's blend, but not Selank. The FDA's Semax briefing says the nominations had been withdrawn and the agency was evaluating the substances at its discretion. That development did not establish a Selank dosage, evaluate the two-peptide blend, or provide a nasal-to-injection conversion.

Selank and DSIP answer different questions

Selank and DSIP sometimes appear on the same sleep-and-stress lists, but they are separate peptides with separate evidence. DSIP is studied around sleep and rest rather than as another form of Selank. Its research amounts belong in the DSIP dosage evidence, not in a Selank chart, and seeing both online is not evidence for combining them.

What a provider considers for the blend

For the Semax/Selank blend, the useful starting point is the person, not the Russian 2.7 mg figure. The review covers the reason for the request, mental-health and neurological history, current medications, prior reactions, and whether a different kind of care fits the concern better. It also accounts for two active peptides and an injectable formulation.

The provider then sets the amount, timing, and follow-up plan for the concentration actually dispensed. That is why a copied nasal schedule can be both precise and wrong. Selank and Semax differ, and combining them does not erase that difference.

A licensed provider reviews every request, and not everyone qualifies. If the blend is prescribed, the label and care plan carry the dose that applies to that prescription.